
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems is expected to experience mid-single digit organic revenue growth and double-digit earnings growth driven by new products and acquisitions, as well as cost reduction efforts. With management executing on their Continued Growth Initiatives (CGI) program, which focuses on improving operating margins and cash flow, the company's strong balance sheet and growing cash flow should allow for further external growth. However, risks include margin and free cash flow performance as well as slower growth in China.
Bears say
Merit Medical Systems is expected to have sluggish organic revenue growth as compared to the previous quarter, mainly due to a decline in OEM sales. However, with the launch of the WRAPSODY Cell-Impermeable Endoprosthesis and the execution of Continued Growth Initiatives, the company may experience mid-single digit or better organic revenue growth and double-digit EPS growth. If the company achieves 9% or higher organic revenue growth driven by recent acquisitions and new product launches, it could potentially lead to a 24x P/E multiple and a share price of $108.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares